Empire BlueCross BlueShield Announces Four New Partnerships to Address Behavioral Healthcare Needs in New York

As Empire works to materially and measurably improve the health of all New Yorkers, these new partnerships support more than 5,500 behavioral healthcare providers to be active in the Empire network, making behavioral healthcare more accessible for members NEW YORK–(BUSINESS WIRE)–Today, Empire BlueCross BlueShield (Empire) is announcing a suite of innovative companies that are joining … [Read more…]

Resilience Becomes Biomanufacturing Resource Partner for California Institute for Regenerative Medicine

Resilience will aid in the development of CIRM grant applications as a biomanufacturing partner with awardees who are developing novel regenerative medicines and cell therapies. SAN DIEGO–(BUSINESS WIRE)–#biomanufacturing—National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, was named by the California Institute for Regenerative Medicine (CIRM) as one of … [Read more…]

GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2

A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma DURHAM, N.C.–(BUSINESS WIRE)–#GeneCentric—GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 or IL-2 therapy and the … [Read more…]

Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer

WALTHAM, Mass.–(BUSINESS WIRE)–Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers, announced today the appointment of Gilles Gallant, BPharm, PhD, FOPQ, to the new position of Chief Development Officer. The company also announced that Mythic co-founder and CEO Alex Nichols, PhD, has … [Read more…]

BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China

Submission seeks marketing authorization for first-line use in combination with chemotherapy in advanced esophageal squamous cell carcinoma CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today … [Read more…]

VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA

AMSTERDAM–(BUSINESS WIRE)–VectorY, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders through vectorized antibodies, announces today that it will present a poster at the Hereditary Disease Foundation 2022 Meeting in Cambridge, Massachusetts, on August 24-27, 2022. The poster shows that VectorY’s AAV vector, dose-dependently … [Read more…]

Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Namodenoson induced a complete response with disappearance of all metastases in a patient who will now continue the treatment under a compassionate use program in Romania Can Fite’s Phase III pivotal study is open for patient enrolment PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary … [Read more…]

New Survey from Vizient Provides Hospital Insights into Biosimilar Adoption and What is Preventing Greater Utilization

IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. announced today the results of its 2022 biosimilar survey, which demonstrate significant biosimilar adoption to hospital formularies, but lagging utilization in patient care. The survey of hospital leaders and pharmacy professionals from Vizient member hospitals across the country found that biosimilars are gaining inclusion in hospital formularies, something long seen as … [Read more…]

Global Teeth Whitening Products Market Report (2022 to 2027) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Teeth Whitening Products Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global teeth whitening products market size reached US$ 5.2 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 7.0 Billion by 2027, exhibiting a CAGR of 5.08% … [Read more…]

Global Preclinical CRO Market Report 2022: Increase in R&D Budget for Drug Development Presents Lucrative Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Preclinical CRO Market Research Report by Services (Bioanalysis and DMPK Studies and Toxicology Testing), End-user, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Preclinical CRO Market size was estimated at USD 4,925.16 … [Read more…]